<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699969</url>
  </required_header>
  <id_info>
    <org_study_id>HN12016</org_study_id>
    <nct_id>NCT03699969</nct_id>
  </id_info>
  <brief_title>A Study Comparing Hypofractionated Dose Escalated VMAT to Conventional CCRT in Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>A Clinical Study Comparing Hypofractionated Dose Escalated VMAT to Conventional CCRT in Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy and toxicity between hypofractionated dose escalated VMAT versus
      conventional concurrent chemoradiation in locally advanced head and neck cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients were randomized to receive either: 70Gy in 35fx in 7wks at 2Gy/fx concurrently with
      weekly cisplatin 40mg/m2 (Arm A) or 74Gy in 33 fractions (fx) in 6.5 weeks at 2.24Gy/fx (Arm
      B). Volumetric Modulated Arc Therapy (VMAT) plans were created for both treatment arms
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control in the two arms</measure>
    <time_frame>33 months</time_frame>
    <description>Local control by RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The progression free survival in the two arms</measure>
    <time_frame>33 months</time_frame>
    <description>The time (in months) from the end of radiotherapy to the date of first progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of toxicity of radiotherapy by CTCAE protocol in the two arms</measure>
    <time_frame>33 months</time_frame>
    <description>The number of patients who develop radiotherapy toxicity as assessed by CTCAE protocol Version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Locally Advanced Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated dose escalated VMAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated dose escalated VMAT radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional concurrent chemoradiation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional concurrent chemoradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated dose escalated VMAT</intervention_name>
    <description>measure the local control, progression free survival and overall survival</description>
    <arm_group_label>Hypofractionated dose escalated VMAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years and ≤70 years old.

          2. Histopathologically confirmed squamous cell carcinoma of head and neck.

          3. Locally advanced tumors (T3-T4 &amp;/or N1-3) (stage IIB, III and stage IV-A: Staging by
             AJCC 7th edition).

          4. Patients not exposed to radical surgery for current disease.

          5. Performance status (ECOG) 2 or less.

          6. No associated co-morbidity with contraindication to chemotherapy.

          7. Normal Hemogram. (ANC ≥1.5x109/L, Platelets count ≥100x109/L, hemoglobin ≥80 g/L)

          8. Accepted renal functions. (BUN &amp; serum creatinine &lt;1.5x upper limit of normal value
             with normal GFR).

          9. Accepted liver functions. (total bilirubin and direct bilirubin &lt; 1.5 x ULN &amp; alanine
             aminotransferase and aspartate aminotransferase &lt; 3 x ULN)

         10. Informed consent.

        Exclusion Criteria:

          1. Patients with distant metastatic lesions, as detected by imaging techniques.

          2. Patients with history of other head and neck malignancies.

          3. Patients with history of previous head and neck irradiation.

          4. Patients with a serious concomitant illness, such as active cardiac disease, severe
             uncontrolled hypertension, or uncontrolled infection.

          5. Women who are pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ehab Saad</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Hypofractionation</keyword>
  <keyword>VMAT</keyword>
  <keyword>head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

